Reuters logo
BRIEF-Endocyte announces worldwide license of its radioligand therapy
October 2, 2017 / 3:31 PM / 3 months ago

BRIEF-Endocyte announces worldwide license of its radioligand therapy

Oct 2 (Reuters) - Endocyte Inc:

* Endocyte announces exclusive worldwide license of phase 3 ready PSMA-targeted radioligand therapy for development in prostate cancer

* Says under the terms of agreement, co has exclusive worldwide rights to developand commercialize PSMA-617

* Announced the completion of a worldwide, exclusive license of PSMA-617from ABX GmbH

* Says under the terms of agreement, Endocyte has made an upfront payment of $12 million to ABX Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below